The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim

Hanny Al-Samkari; Alexandra Schifferli; Tomas J Gonzalez-Lopez

doi:10.1111/bjh.19327

The problem of immune thrombocytopenia refractory to both eltrombopag and romiplostim

Br J Haematol. 2024 Apr;204(4):1143-1145. doi: 10.1111/bjh.19327. Epub 2024 Feb 6.

Authors

Hanny Al-Samkari¹, Alexandra Schifferli², Tomas J Gonzalez-Lopez³

Affiliations

¹ Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Department of Hematology/Oncology, University Children's Hospital Basel, Basel, Switzerland.
³ Hematology Department, Hospital Universitario de Burgos, Burgos, Spain.

PMID: 38319005
DOI: 10.1111/bjh.19327

Abstract

Immune thrombocytopenia refractory to multiple thrombopoietin receptor agonists remains a challenging clinical problem. This commentary discusses and contextualizes the recent report on this entity from Moulis and colleagues, and how to move forward with these patients. Commentary on: Moulis et al. Difficult-to-treat primary immune thrombocytopenia in adults: Prevalence and burden. Results from the CARMEN-France Registry. Br J Haematol 2024;204:1476-1482.

Keywords: eltrombopag; immune thrombocytopenia; refractory; romiplostim; thrombopoietin receptor agonist.

MeSH terms

Adult
Benzoates / therapeutic use
Humans
Hydrazines / therapeutic use
Purpura, Thrombocytopenic, Idiopathic* / drug therapy
Pyrazoles*
Receptors, Fc / therapeutic use
Receptors, Thrombopoietin / agonists
Recombinant Fusion Proteins / therapeutic use
Thrombocytopenia* / drug therapy
Thrombopoietin / therapeutic use

Substances

romiplostim
eltrombopag
Receptors, Thrombopoietin
Thrombopoietin
Benzoates
Hydrazines
Receptors, Fc
Recombinant Fusion Proteins
Pyrazoles